

ANNUAL REPORT 2025

TABLE OF CONTENTS

Presidential Introductory Message.....	2
EANO Welcomes President Elect: Roberta Rudà.....	3
Disparity and Inclusion Committee	4
Educational Committee.....	5
Brain Tumour Advocacy Committee (BTAC)	6
Guidelines Committee	7
Nurse & Allied Health Professional Committee (NAC).....	8
Publication Activity Committee.....	9
Scientific Committee	9
Youngsters Committee	10
EANO Tumor Board 2025: Multidisciplinary Management of Patients with Glioma ...	11
EANO Activities	12
EANO Meeting 2026	18

PRESIDENTIAL INTRODUCTORY MESSAGE

Michael Platten, EANO President 2024-2026



Michael Platten © Private archive

Dear EANO members, friends and colleagues,

On my way to the WFNOS 2025 meeting it is a great pleasure to look back on yet another remarkable year for our association. The recent meeting in Prague was an outstanding success and a wonderful reflection of the strength, diversity, and collaborative spirit within the EANO community. We were thrilled to welcome a record number of attendees from all over the world, many of whom attended the EANO meeting for the first time. They were excited about the scientific breadth and depth of the meeting spanning from groundbreaking basic science to practice changing clinical applications. The diversity of attendees and topics presented highlighted once again how vibrant and rapidly advancing the field of neuro-oncology has become. This is also reflected by the participation of patient representatives and caregivers owing to the impactful activities of the newly formed Brain Tumor Advocacy Committee.

My warmest thanks go to all of you for your commitment, enthusiasm, and contributions throughout the year. I would also like to express my sincere gratitude to the local hosts in Prague, whose dedication and hospitality helped create an exceptional environment for scientific exchange, networking, and education. The energy and engagement across all committees, task forces, and initiatives have been truly inspiring, and you will find an overview of their activities in the pages that follow.

EANO's ongoing efforts in fostering education, supporting early- and mid-career professionals, expanding outreach, and strengthening international collaboration continue to shape our mission. We are delighted to see the growing impact of the EANO School in its 2nd edition, the EANO Tumor Board, the Youngster Journal Club, and our partnerships with our national and international partner societies. The first issue of the new Neurooncology Pediatrics Journal is not only a testimony of the strong partnership with the Society for Neuro-Oncology and the Asian Society for Neuro-Oncology but our partnerships with the pediatric neurooncology community. All these activities form an essential foundation for supporting our community and advancing research and patient care.

In 2026 we will launch the EANO Seminars with an inaugural meeting in Bucharest to provide a comprehensive course in Neuro-Oncology to our community. Preparations for next year's scientific meeting and educational day in Rome are already in full swing, and we look forward to another dynamic gathering that will bring together clinicians, scientists, nurses, allied health professionals, and industry partners from around the world. As we carry forward the momentum from Prague, we will continue working to broaden participation, encourage innovation, and support excellence across all areas of neuro-oncology.

Thank you for being part of this community and for the many ways you help shape EANO's mission. I look forward to another exciting year of progress, connection, and shared purpose.

Michael Platten

EANO President 2024-2026

EANO EXECUTIVE AND GENERAL BOARD MEMBERS 2024-2026

Executive Board 2024-2026

President: Michael Platten, DE
 Past-President: Susan Short, UK
 Treasurer: Manuel Valiente, ES
 Anna Berghoff, AT
 Emilie Le Rhun, FR/CH
 Christian Marwin, DE
 Giuseppe Minniti, IT
 Stephen J. Price, UK
 Evangelia Razis, GR
 Lena Roselund, SE

General Board 2024-2026

Florien Boele, UK
 Norbert Galldiks, DE
 Mihaela Lorgier, SLO/UK
 George Petrescu, RO
 Karin Piil, DK
 Matthias Preusser, AT
 Aleksi Sedo, CZ

EANO WELCOMES PRESIDENT ELECT: ROBERTA RUDÀ

Dr. Roberta Rudà is **Professor of Neurology** at the University of Turin. She has been involved in Neuro-Oncology for up to 25 years.

From 2022 is the **Chair of the Division of Neuro-Oncology** of the Department of Neuroscience at the University of Turin. She is the Coordinator of the Multidisciplinary Brain Tumor Board, City of Health and Science Hospital/University of Turin.

Professor Rudà has been **member of the EANO Executive Board** from 2016 to 2024. She has led two European Guidelines: the EANO Guideline on Ependymal tumors and the EANO-EURACAN-SNO Guideline on Rare glial, glioneuronal and neuronal tumors (both published in Neuro-Oncology).

From 2017 to 2022 she held the position of **President of the Italian Association of Neuro-Oncology (AINO)** and from 2022 is the **Co-Chair** of the **Panel of Neuro-Oncology of EAN** (European Academy of Neurology).

She is Member of the **RANO Groups** on Seizures, Liquid biopsy, Leptomenigeal diseases, Resect and PET-RANO. Moreover, she is member of the Brain Tumor Group of EORTC, where is leading the Ependymoma subgroup within the EORTC 2013 Glio-Rare study.

The **major research areas** include: primary brain tumors with particular interest in lower grade gliomas, rare brain tumors (in particular ependymomas) and brain tumor-related epilepsy. Translational research, functional neuroimaging and neurological complications of cancers (in particular neoplastic meningitis) have been a focus of interest as well.

Professor Rudà has been **Principal Investigator** in several national and international **clinical trials**.

She has **published more than 250 papers** in highly impacted Journals, and several Chapters in international books.

EANO Welcomes Roberta Rudà as President Elect. Her presidency will begin after the Rome Meeting 2026.



Roberta Rudà © Private archive

DISPARITY AND INCLUSION COMMITTEE

The Disparity and Inclusion Committee, under the 2025 leadership of Karin Piil (DK), and Su-san Short (UK) and Barbara Kiesel (A), prioritize inclusivity as fundamental values. We believe in creating an environment where all participants, regardless of background or identity, can engage meaningfully and feel valued. Therefore, we encourage all attendees to uphold these values by respecting others, adopting an inclusive attitude, and reporting any incidents that may undermine inclusivity.

We are delighted to announce outstanding gender representation at the EANO Meeting 2025, reflecting our commitment to diversity and inclusion. The EANO meeting features a diverse mix of attendees from various career stages and specialties, ranging from newcomers to seasoned professionals.

During the EANO meeting in 2025, our collaboration with the Scientific Committee resulted in organizing an engaging oral session "Palliative care in Neuro-Oncology", with 4 invited speakers and 3 abstract presentations. We were thrilled with the excellent turnout for this session, as a full room of engaged attendees listened attentively to presentations by the presenters. The session had plenty of insightful questions to foster great scientific dialogue about palliative care and how to strengthen this field.

As always, we monitor the diversity of attendees, speakers, and chairs by age, profession, and nationality. In the survey, nearly everyone agreed that EANO 2025 provides a welcoming and inclusive environment where they feel safe.

Also, we are proud to have awarded three Travel Scholarships 2025 to individuals from countries that have been underrepresented so far in EANO. Members of our committee met in person with the recipients, and they were properly welcomed to EANO. It was with great pride that we, as a Diversity Committee, presented the 2025 Diversity and Inclusion Award to Dr. Florian Boele. She received the award in recognition of her outstanding efforts to strengthen inclusion within our neuro-oncology community.

In collaboration with the Youngsters, the NAC and the EANO leadership, we ran an observational survey on the chairing roles during EANO 2024 sessions. The survey findings were poster-presented this year, and will be submitted for publication ultimo 2025. This effort is led by Jan-Michael Werner (DE), George Petrescu (RO), Florian Boele (UK), and Karin Piil (DK).

In 2025 we have worked with the NAC's initiative to establish a patient advocacy group (BTAC) within EANO, and are pleased to work with Marie-Therese Gubi. In collaboration with EANO conference manager Lydia Schnedl, we have created a 'How-to' guide" to help EANO conference promote diversity of attendance and inclusivity of participation at events.

In collaboration with The Educational Committee, we are invited to systematically assess topics/priorities at next years program, through the lens of disparity. Further, we collaborate on the future EANO Guideline on Rehabilitation, and Evangelia Razis, (Greece) is co-leading a project on fertility that we follow closely.

Project for 2026 include exploring glioma management practices in the European Outermost Regions to inform future strategies for strengthening collaboration, this is led by Julio Plata-Bello, (Tenerife, Spain). Another study aims to investigate Health and Care Needs in the Elderly Neuro Oncological Population. This is led by Anastasia Vernadou (Greece).

Susan Short (UK) is stepping down, and we owe her our sincere thanks for her dedication, hard work, and consistent support in meetings and discussions that have driven our initiatives forward. We are pleased to announce that Barbara Kiesel (Austria) is now the chair. Thanks to all the members who have worked on our strategies.

Looking ahead to 2026, we have a committee with dedicated members advancing the committee's mission with renewed focus and enthusiasm.

THE DISPARITY COMMITTEE COMPOSITION 2025-2026

Chair: Barbara Kiesel, Austria, Neurosurgeon
 Past chair: Karin Piil, DK, Associate Professor, Neuro-oncology
 Anastasia Vernadou, Greece, Medical Oncologist
 Caroline Hertler, Switzerland, Medical Oncologist
 Evangelia Razis, Greece, Medical Oncologist (Board member representative)
 Julia Furtner-Srajer, Austria, Neuroradiologist
 Julio Plata-Bello, Spain (Tenerife), Neurosurgeon
 Mayen Briggs, UK, Neuropathology (Social Media task force Representative)
 Miarka Lauirtz, Germany, Clinician Scientist (Youngster Representative)
 Stephen Price, UK, Neurosurgeon (Board member representative)
 Marie-Therese Gubi, Medical student, Austria (BTAC representative)

EDUCATIONAL COMMITTEE

Under the leadership of Mihaela Lorgier (Committee Chair, 2024–2026), the Educational Committee, working closely with the EORTC Brain Tumor Group, designed and delivered a high-quality Educational Day program for the EANO 2025 Meeting in Prague, and was involved in the design of the Education Day program for the 2025 WFNOS/SNO Annual Meeting in Honolulu. This dynamic and forward-thinking committee continues to drive innovation across EANO's educational portfolio.

In 2025, the committee successfully launched the third round of the EANO Mentorship Program, strengthening opportunities for professional development and international collaboration. In parallel, the committee continued advancing EANO's learning strategy through the EANO School of Neuro-Oncology, an online educational curriculum that began its second two-year cycle in October 2024 and is now progressing toward its final year in 2026. This year also marked the inaugural EANO Tumor Board: Multidisciplinary Management of Patients with Glioma, held as a pre-congress event in Prague, reflecting EANO's commitment to practical, case-based learning and multidisciplinary excellence in patient care.

Looking ahead, 2026 will feature a strong educational program, including the EANO Seminars in Bucharest, taking place from 14–23 March 2026, as well as the next EANO Tumor Board on 12 March 2026. The year will also see the opening of a new application round for the EANO School of Neuro-Oncology, offering another opportunity for participants to engage in this structured, long-term curriculum. Finally, 2026 will include elections for new members of the Educational Committee, and we warmly invite enthusiastic colleagues who are committed to advancing neuro-oncology education to apply and join the team.

EDUCATIONAL COMMITTEE COMPOSITION 2024–2026

Mihaela Lorgier, United Kingdom/ Slovenia (Chair)
Stephen Price, United Kingdom (Past-chair)
Matthijs van der Meulen, The Netherlands (Next-chair)
Filip De Vos, The Netherlands
Pinelopi Gkogkou, United Kingdom
Laetitia Lebrun, Belgium
Lena Rosenlund, Sweden
Roberta Rudà, Italy
Mehdi Touat, France
Anouk van der Hoorn, The Netherlands
Carlos Velásquez, Spain
Iris Verploegh, The Netherlands (Youngster Representative)

BRAIN TUMOUR ADVOCACY COMMITTEE (BTAC)

The Brain Tumour Advocacy Committee successfully launched in June 2025, marking a significant milestone in EANO's commitment to patient and caregiver engagement. In its first six months, BTAC has established robust governance structures, built strong collaborative relationships across EANO committees, and initiated strategic priorities focused on health equity, patient voice integration, and knowledge translation.

Committee establishment and governance. Helen Bulbeck chairs the committee with Kathy Oliver as vice chair. Nine members represent diverse backgrounds including patients, caregivers and patient organisation representatives from Sweden, Greece, Germany, Czech Republic, Poland, and other European countries. The committee has finalised its Terms of Reference (November 2025), developed role profiles for advocate members, and established meeting protocols with quarterly meetings scheduled through 2026, including one annual face-to-face meeting at the EANO conference and three virtual meetings per year.

Strategic priorities and collaboration. BTAC has established four core strategic priorities: health equity and access, patient voice integration, knowledge translation and communication, and education and capacity building. The committee has successfully embedded representatives across all EANO committees, including the Disparity Committee (focusing on health inequalities), the Nurse & Allied Health Professional Committee (contributing to supportive care track design), the Publishing Activity Committee (developing lay summaries and patient advocacy sections), the Youngsters Committee (planning podcast collaborations), and the Education Committee (contributing patient perspectives to educational programmes).

Key projects and initiatives. The committee is collaborating with EuroCAN on a one-page patient information leaflet covering brain tumours, glioblastoma, and oligodendroglioma, with multi-language distribution and QR code integration planned. BTAC is also reviewing a draft patient glioma guide originally developed with Servier input, with plans to transfer ownership to EANO for independence and expand content to include IDH mutant gliomas. Committee members attended and contributed to the EANO conference in Prague (October 16-19, 2025), participating in sessions on shared decision-making, hormonal impact on brain tumours, paediatric neuro-oncology, and tumour board discussions.

Achievements and future direction. The committee has achieved strong member engagement with established mentoring systems for new members and clear governance structures. BTAC has successfully integrated into EANO's committee structure, achieving representation across all major committees and building collaborative relationships with committee chairs. Looking ahead to Year 2, immediate priorities include completing membership expansion with two additional members (one patient, one caregiver), finalising the patient leaflet for publication, completing the glioma guide review, and launching a patient information hub. Mid-term goals focus on initiating health equity research projects, launching a podcast series, and developing an advocacy speakers bureau.

Recommendations to the board. The committee requests continued financial and administrative support for BTAC activities, approval for membership expansion to strengthen representation, and strategic integration ensuring BTAC representation in all relevant EANO strategic planning discussions.

Conclusion. The Brain Tumour Advocacy Committee has successfully completed its inaugural phase, establishing a strong foundation for patient and caregiver engagement within EANO. With robust governance structures in place, active participation across EANO committees, and meaningful projects underway, BTAC is well-positioned to deliver significant impact in advancing patient-centred care and research in neuro-oncology. The committee's work exemplifies EANO's commitment to ensuring that patients and caregivers are genuine partners in shaping the future of neuro-oncology care, research, and policy across Europe. The chair and vice chair are grateful for EANO's support in establishing this new committee.

BTAC COMPOSITION 2025-2027

Anna Berankova, CZ

Jolijn Boer, GE

Helen Bulbeck (chair), UK

Marie – Therese Gubi, AT

Charles La Faye, NL

Kathy Oliver (vice chair), UK

Evangelia Razis, GR

Lena Rosenfeld, SE

Maria Tsiogka, GR

GUIDELINES COMMITTEE

GUIDELINES COMMITTEE COMPOSITION 2024-2026

Emilie Le Rhun, Switzerland (Chair 2024-2026)
Matthias Preusser, Austria (Past-Chair)
Petter Brandal, Norway (second term)
Johnny Duerinck, Belgium (first term)
Enrico Franceschi, Italy (second term)
Julia Furtner-Srajer, Austria (second term)
Norbert Galldiks, Germany (second term)
Marjolein Geurts, The Netherlands (second term)

Giuseppe Lombardi, Italy (first term)
Christian Mawrin, Germany (second term)
Mirjam Renovanz, Germany (second term)
Susan Short, United Kingdom, Board representative (first term)
Philipp Sievers, Germany (first term)
Emeline Tabouret, France (second term)
Felix Ehret, Germany (Youngster Representative, first term)

Publications 2025

EANO alone

Updated EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection-Update 1.

van den Bent MJ, Franceschi E, Touat M, French PJ, Idbaih A, Lombardi G, Rudà R, Schweizer L, Capper D, Sanson M, Wesseling P, Weller M, Eoli M, Anghileri E, Bielle F, Eusikirchen P, Geurts M, Wen PY, Preusser M. *Neuro Oncol.* 2025 Feb 10;27(2):331-337. doi: 10.1093/neuonc/noae213. PMID: 39387386

EANO and other Societies

EANS-EANO Guidelines on the extent of resection in gliomas.

Goldbrunner R, Foroglou N, Signorelli F, Schucht P, Jakola AS, Minniti G, Rola R, Renovanz M, Preusser M, Furtner J, Grossman R, Mawrin C, Demetriades A, Weller M, Simon M. *Neuro Oncol.* 2025 Sep 17;noaf217. doi: 10.1093/neuonc/noaf217. Online ahead of print. PMID: 40973061

Update to the RANO working group and EANO recommendations for the clinical use of PET imaging in gliomas.

Galldiks N, Lohmann P, Aboian M, Barajas RF Jr, Breen WG, Ivanidze J, Johnson DR, Kaufmann TJ, Kim MM, Mair MJ, Minniti G, Muther M, Nabavizadeh A, Palmer JD, Rudà R, Smits M, Tolboom N, Veldhuijzen van Zanten SEM, Veronesi MC, Werner JM, van den Bent M, Chang SM, Langen KJ, Law I, McConathy J, Mehta M, Preusser M, Short SC, Soffietti R, Vogelbaum M, Weller M, Wen PY, Tonn JC, Albert NL. *Lancet Oncol.* 2025 Aug;26(8):e436-e447. doi: 10.1016/S1470-2045(25)00193-7. PMID: 40744043

Joint EANM/EANO/RANO/SNMMI practice guideline/procedure standard for PET imaging of brain metastases: version 1.0.

Verger A, Tolboom N, Cicone F, Chang SM, Furtner J, Galldiks N, Gempt J, Guedj E, Huang RY, Johnson DR, Law I, Le Rhun E, Short SC, Bent MJVD, Weehaeghe DV, Vogelbaum MA, Wen PY, Albert NL, Preusser M. *Eur J Nucl Med Mol Imaging.* 2025 Apr;52(5):1822-1839. doi: 10.1007/s00259-024-07038-5. Epub 2025 Jan 7. PMID: 39762634

ESTRO-EANO guideline on target delineation and radiotherapy for IDH-mutant WHO CNS grade 2 and 3 diffuse glioma.

Baumert BG, P M Jaspers J, Keil VC, Galldiks N, Izycka-Swieszezewska E, Timmermann B, Grosu AL, Minniti G, Ricardi U, Dhermain F, Weber DC, van den Bent M, Rudà R, Niyazi M, Erridge S. *Radiother Oncol.* 2025 Jan;202:110594. doi: 10.1016/j.radonc.2024.110594. Epub 2024 Oct 24. PMID: 39454886

Theranostics for Meningioma on the Rise: New EANM/EANO/RANO/SNMMI Guidelines Pave the Way to Improved Patient Outcomes Using Radiolabeled Somatostatin Receptor Ligands.

Albert NL, Preusser M, Galldiks N, Ivanidze J. *J Nucl Med.* 2025 Jan 3;66(1):24-25. doi: 10.2967/jnumed.124.268314. PMID: 39389626

Guidelines in preparation

EANO alone

Glioma guidelines (Lead: M Weller)

Survivorship in brain tumors (Lead: E Franceschi, E Le Rhun)

Update on the meningioma guidelines (Lead R Goldbrunner)

Rehabilitation (Lead L Rosenblum, P Hau)

Testing of familial gliomas (Lead R Weber)

Nursing guideline on supportive care and rehabilitation (Lead L Rosenblum, E Le Rhun)

Radionecrosis (Lead E Razis)

Palliative care (Lead A Pace)

EANO and other Societies

Systemic Pharmacotherapy for Primary Brain Tumors (Lead M Preusser, M Weller), with ESMO

BRAF-mutant Gliomas: A SNO-EANO Consensus Review on Clinical Management and Future Directions (Lead M Geurts)

SNO-EANO Consensus Review on IDH-mut Glioma Diagnosis, Management and Future Directions (Lead M Platten)

Re-irradiation primary brain tumors / RT details (lead ESTRO)

Adult lower grade / RT details (lead ESTRO)

Surgical adjuncts (lead EANS, R Goldbrunner, M Simon)

The oncological relevance of the resection cavity and its infiltrative margins in gliomas:

an EANO/SNO review (divided in Part 1 and 2) (Lead P Karschnia, J Tonn)

Extent of resection (lead EANS, R Goldbrunner)

Planned

EANO alone

Update EANO Brain Metastases (Lead E Le Rhun, M Preusser)

Sex and gender in neuro-oncology (E Le Rhun)

AYA (Lead E Razis)

Driving (E Le Rhun)

EANO EHA-ESMO

PCNSL, discussions between societies to start when currently available guidelines need update (EANO Lead M Preusser, M Weller)

Status: approved by the committee

Other business

SOP are in preparation

NURSE & ALLIED HEALTH PROFESSIONAL COMMITTEE (NAC)

2025 marks the 5-year anniversary of this committee. We continue to grow as a community building a robust network of nurses and allied health professionals fostering inspiration and numerous impactful projects. At EANO in Prague we said goodbye to six of our members, Karin Piil, Isabelle Ryden, Marike Donders-Kamphuis, Sara Melhuish, Sara Marie Juel Nordentoft, Helle Sørensen von Essen, having served their membership term on our committee. We are grateful for their time, commitment, and dedicated service to the NAC Committee over the past four years. We would like to extend our sincere appreciation to Dr Karin Piil whose contributions have been greatly valued.

Nurse and Allied Health Professionals Education day track

EANO 2025 was our first year with our new track name 'supportive care'. The day included 16 invited speakers from 8 countries, with 62 registered attendees. Topics included providing optimal care within healthcare context restraints, managing difficult quality of life conversations, caring for vulnerable patient and carers and challenges in the management of non-malignant brain lesions. We held our third EANO NAC dinner which was open to all EANO attendees with a nursing/AHP background. A total of 50 colleagues from 15 countries attended.

Nurse and Allied Health Professionals awards

EANO 2025 showcased outstanding research from our nursing and AHP members. A special congratulations to Dr Maija Reblin who was awarded the Nurse and AHP research award 2025.

The NAC committee was delighted to honour members for their exceptional research contributions. Our outstanding science-merit based awards went to: Shaista Meer (UK), Sarah Kendal (UK), Lotte Weyhenmeyer (Sweden), Asa Munkhammar (Sweden), Helle Sorensen von Essen (Denmark)

NAC travel scholarships were awarded to Ingrid Berggren (Sweden), Loredana Dinapoli (Italy), Andrea Rioli (Spain).

NAC members were given the opportunity to apply for a travel scholarship to attend EANO 2025 in Prague; Sara Melhuish and Isabelle Ryden were successful.

Ongoing NAC project

'A collective insight into nurses and AHPs working in neuro-oncology'

The focus group brings together members of the NAC to share collective perspectives on working within neuro-oncology. By drawing on the lived experiences of nurses and AHPs, the aim is to highlight both the challenges and rewards of practice in neuro-oncology, while generating practical strategies and reflections that may inform and support others entering the field. Focus groups were held in September to spark discussions on experiences of building a career in neuro-oncology. Following this themes were generated to discuss key points and a more in-depth discussion was held in a second series of focus groups in October. The next steps are to generate key statements and rank these through online survey. Results will follow in early 2026.

Collaborative projects

The NAC committee is extremely proud of the number of successful collaborative projects. Some of the highlights from 2024/2025 include;

NAC, Disparity committee and Youngsters

'Chairing scientific sessions at international neuro-oncology meetings: An EANO guide for early-career professionals' was published in Neuro-Oncology in Practice in December 2024. This collaboration between disciplines summarises the core tasks involved in chairing and provides advice regarding common issues that may arise for EANO members undertaking the chairing role.

<https://doi.org/10.1093/nop/npae060>

This group undertook a shared follow-up project at EANO 2024: observing the chairs' introductions of speakers and management of sessions during the EANO 2024 conference. An abstract was presented at EANO 2025 [Werner, J., Petrescu, G. E., Preusser, M., Platten, M., Chalmers, A., Short, S., & Piil, K. (2025). P16. 04. B The role of chairpersons in quality and inclusivity of scientific discussions' an EANO survey. *NeuroOncology*, 27(Supplement_3), iii153-iii153] and a manuscript is nearly ready for submission.

Social media

Our LinkedIn group for Nurses and health care professionals with an interest in Neuro-Oncology has seen a significant increase in members, up from 173 in 2023 to 398 members in 2025.

Dr Lena Rosenlund and Aoife Williamson are the NAC representatives on the new EANO Social Media task force. SoMe was created to increase the visibility of EANO's Social Media activities and help promote and report on the EANO meeting.

New membership

We had the challenging job of choosing five new members from a very strong pool of applicants. Each candidate's CV and cover letter was independently evaluated, while also aiming for a balanced mix in terms of gender, clinical and research backgrounds, and geographic representation. Chairing the newly formed committee will be Aoife Williamson (UK).

NAC Committee composition

Aoife Williamson (UK) chair elect 2025-2027

Florien Boele (UK) past chair 2023-2025

Sharon Fernandez (UK)

Martin Klein (Netherlands)

Georgia Halkett (Australia)

Loredana Dinapoli (Italy)

Maria Camilla Mathiasen (Denmark)

Christelle Smit (United Kingdom)

Tomas Gomez Vecchio (Sweden)

Lena Rosenlund (Sweden) Board representative

Helen Bulbeck (UK) Advocacy group representative

PUBLICATION ACTIVITY COMMITTEE

The Publishing Activity Committee supports the Executive Board of EANO and consists of Editors that represent EANO in the following journals: *Neuro-Oncology*, *Neuro-Oncology Practice*, *Neuro-Oncology Advances*, and *Neuro-Oncology Pediatrics*. All these journals are published by Oxford University Press (OUP).

The flagship journal *Neuro-Oncology* is owned by the US partner of EANO, the Society of Neuro-Oncology (SNO), with EANO as a minority shareholder. Furthermore, *Neuro-Oncology* is the official journal of the SNO, the Japan Society for Neuro-Oncology (JSNO), the EANO, and the World Federation of Neuro-Oncology Societies (WFNOS). *Neuro-Oncology Advances* and *Neuro-Oncology Practice* are sister journals of *Neuro-Oncology* and published in partnership with the EANO. In mid-2025, the journal *Neuro-Oncology Pediatrics*, jointly owned by SNO and EANO, was launched as the fourth title in the Neuro-Oncology family of journals.

The main tasks of the committee are to ensure scientific representation and strategic orientation of EANO in these journals, providing a link between EANO and the journal publisher OUP and promoting the publication activities within the EANO membership.

The committee consists of the EANO Editors (i.e., Associate Editors, Executive Editors, and possibly Editor-in-Chief) in the various publication sectors, the EANO Treasurer, the EANO President, and the EANO Past President.

On behalf of EANO, Professor Wolfgang Wick was appointed in 2025 as new Editor-in-Chief of *Neuro-Oncology Advances*. In addition, Professor Norbert Galldiks was appointed as new Executive Editor of *Neuro-Oncology Advances*.

PUBLICATION ACTIVITY COMMITTEE COMPOSITION 2025-2026

Chair: Norbert Galldiks, DE (Associate Editor NOA & NOP, appointed Executive Editor NOA)

Next Committee Chair/Chair Elect: Florian Boele, UK (Associate Editor NO)

Past-chair: Martin Taphoorn, NL (Editor-in-Chief NOP)

Marta Alonso, ES (Executive Editor NOPed)
 Francois Ducray, FR (Associate Editor NOA)
 Monika Hegi, CH (Associate Editor NO)
 Johan A.F. Koekkoek, NL (Associate Editor NOP)
 Katrin Lamszus, DE (Associate Editor NOA)
 Philipp Lohmann, DE (Associate Editor NOA)
 Giuseppe Minniti, IT (Associate Editor NOA & NOP)
 Karin Piil, DEN (Associate Editor NOP)
 Michael Platten, DE (EANO President, Associate Editor NO)
 Matthias Preusser, AT (Executive Editor NO)
 Patrick Roth, CH (Executive Editor NOP)
 Felix Sahm, DE (Associate Editor NOA)
 Susan Short, UK (EANO Past President, Associate Editor NOA)
 Abigail Suwala, DE (Associate Editor NOP)
 Ghazaleh Tabatabai, DE (Associate Editor NOA)
 Manuel Valiente, ES (EANO Treasurer)
 Wolfgang Wick, DE (Executive Editor NOA, appointed Editor-in-Chief NOA)

SCIENTIFIC COMMITTEE

The Scientific Committee, with the support of the Educational Committee, the Youngsters Committee, and the Disparity Committee, oversees and coordinates the scientific programme of the annual EANO Meetings. Its main tasks include inviting speakers, shaping the scientific programme, reviewing and selecting submitted abstracts, and managing nominations for awards that recognise outstanding contributions to the field of neuro-oncology.

EANO works closely with national and international scientific societies to ensure that the meeting highlights the latest advances in neuro-oncology while meeting the high-quality standards required of a provider of continuing medical education. The Scientific Committee also contributes to EANO's webinar programme, which offers high-quality scientific content to EANO members throughout the year. This includes the "Best of SNO-EANO" webinar series, showcasing key messages from the EANO and SNO annual conferences since 2022.

Overall, the EANO 2025 scientific programme has been very well received by members, as reflected by record numbers of both attendees and submitted abstracts. This success is the result of sustained efforts over recent years to make the conference increasingly attractive—bringing together cutting-edge clinical and scientific developments, engaging leading experts in neuro-oncology, and providing an ideal platform for presenting the work of not only established clinicians and researchers, but also the many trainees who attend EANO.

SCIENTIFIC COMMITTEE COMPOSITION 2025-2026

Chair: Giuseppe Minniti, IT

Past-chair: Manuel Valiente, ES

Next Chair: Anna Berghoff, AT

Thomas Booth, UK

Anna Golobiewska, LU

Linda Douw, NL

Gaetano Gargiulo, DE

Dieter Henrik Heiland, DE

Maximilian Mair, AT (Youngster Representative)

Asgeir Jakola, SE

Estela Pineda Losada, ES

Michael Platten, DE (EANO President)

Anneli Ozanne, SE

Felix Sahm, DE

Roman Sankowski, DE

Aleksi Sedo, CZ (EANO Meeting President 2025)

Luca Tiberi, IT

Georg Widhalm, AT

YOUNGSTERS COMMITTEE

The Youngsters Committee (George Petrescu, RO (chair); Francesco Bruno, IT; Felix Ehret, DE; Antonio C. Fuentes-Fayos, ES/USA; Maximilian Mair, AT; Maximilian Mastall, CH; Lauritz Miarka, DE; Giulia Sprugnoli, IT; Andrada Turcas, RO; Iris Verploegh, NL; Jan M. Werner, DE (Past-Chair); and Emilie Le Rhun, CH (Mentor Executive Board)) continues to develop activities focused on early-career professionals from the field of Neuro-Oncology by contributing to the annual EANO Meeting and Educational Day program.

In 2025, the EANO Youngsters Committee was involved in several successful projects. The Youngsters scientific track was well received during the 20th EANO Meeting in Prague. One of the highly appreciated sessions of the EANO Meeting remained the Pro & Con Session, which once again promoted lively scientific debates. We are therefore grateful to the speakers who participated (Mehdi Touat, Anna Berghoff, Alberto Gallotti, Johnny Duerinck, Raphael Bodensohn, and Tomas Kazda) and congratulate them for receiving the Youngsters Medals. Other very fruitful sessions included the collaboration with the CSNO, which addressed modern imaging and response assessment tools, as well as a joint session with the EORTC that focused on clinical trial planning. The Mentoring Session was once again successful, focusing on storytelling in research and clinical practice. The collaboration with the CBI resulted in a very well-attended and engaging career development session that featured a great panel of speakers to whom we extend our gratitude (Roel Verhaak, Mariella Filbin, Ghazaleh Tabatabai, and Martin van den Bent).

In the upcoming year, we will continue our successful projects, such as the Journal Club and our collaboration with all the other EANO Committees, and we are also planning to launch new projects, such as the Podcast Series, which will consist of interviews with leading specialists from the field of neuro-oncology.



Youngsters Committee © EANO



Pro&Con Session_Youngsters Committee © EANO

EANO TUMOR BOARD 2025: MULTIDISCIPLINARY MANAGEMENT OF PATIENTS WITH GLIOMA

On October 15, 2025, a multidisciplinary educational event on the management of glioma was held in Prague as a pre-event to the EANO Meeting 2025. The session brought together residents, specialists, and nurses from across Europe and beyond, highlighting the international commitment to advancing patient-centered, multidisciplinary care in neuro-oncology.

Chaired by Stephen Price (United Kingdom) and Matthijs van der Meulen (The Netherlands), the program focused on real-world, case-based discussions and featured a diverse faculty of international and local experts from neurosurgery, oncology, radiology, pathology, nursing, and supportive care. A defining strength of the meeting was the consistent integration of the patient perspective, with shared decision-making and patient involvement embedded throughout the program and reinforced by the participation of a patient representative Anna Berankova.

Three interactive case discussions formed the backbone of the session, complemented by expert lectures addressing practical challenges in glioma care, including imaging assessment, molecular diagnostics, surgical recovery, and emerging treatment strategies. A diverse panel of international experts was joined by local Czech specialists, reinforcing the value of integrating global expertise with regional clinical practice.

Building on the success of the Prague pre-event, the next multidisciplinary glioma meeting will take place in Bucharest on March 12, and registration is now open. The upcoming event will continue to promote international collaboration, multidisciplinary learning, and patient-centered approaches in neuro-oncology.

This educational activity was supported by an independent educational grant from Servier.



EANO Tumor Board © EANO

EANO ACTIVITIES

EANO SCHOOL OF NEURO-ONCOLOGY

The EANO School of Neuro-Oncology is a two-year, in-depth educational program delivered virtually over seven weekend modules and in-person kick-off day. The first cycle began in October 2022 and was successfully completed with the final examination in summer 2024.

The second cycle, which has welcomed twice as many participants, opened with an in-person kickoff day in Glasgow in October 2024. Seven further modules have been running throughout 2025–2026, with expanded teaching time of 12 hours per weekend and a curriculum covering Basic and Translational Research, Gliomas, Extra-axial Tumors and CNS Lymphoma, Pediatric Neuro-Oncology, Rare Primary CNS Tumors in Children and Adults, Metastases to the CNS, and Supportive Care.

EANO is particularly proud to see alumni from the first cycle returning to contribute as weekend chairs and co-organizers, helping to shape and strengthen the next generation of the program. During this year's EANO Meeting in Prague, an informal gathering of current participants and alumni took place, providing a valuable opportunity to reconnect, exchange experiences, and celebrate the growing EANO School community.

We are pleased to share that the next application round for the EANO School of Neuro-Oncology will open at the end of February 2026, with an in-person kickoff day planned in Rome prior to the EANO 2026 Meeting.

Looking ahead, the active participation of teachers, students, and alumni strengthens the EANO School as both a premier educational program and a collaborative community for advancing neuro-oncology knowledge.



EANO School Meet-up © EANO



EANO School Meet-up © EANO

EANO MENTORSHIP PROGRAM

The EANO Educational Committee launched its first Mentorship Program in spring 2022, pairing six applicants with six volunteer mentors from different areas of Neuro-Oncology. The program was designed for mentees to develop a specific project in collaboration with their mentor over the course of the year, providing hands-on experience and practical skills in project development. This inaugural round concluded at the EANO Meeting in Rotterdam 2023.

The program was relaunched for a third round in summer 2025, reflecting significant growth and engagement within the EANO community. A record 46 volunteer mentors offered their expertise—nearly eight times the number available in the first cycle—while 33 mentor-mentee pairs were formed, compared to just six in the initial round. Collaborations began in autumn 2025, with several pairs meeting in person during a mentorship coffee meet-up at the EANO Meeting 2025.

In the coming months, surveys will track the progress of these pairs and their projects, supporting the continued development of participants and ensuring the program's lasting impact. This expansion highlights the Mentorship Program's success in fostering collaboration, professional growth, and an active, engaged community within EANO. We extend our sincere thanks to all volunteer mentors for generously dedicating their time, knowledge, and guidance to support the next generation of neuro-oncology professionals.

EANO SEMINARS: FOUNDATIONS IN NEURO-ONCOLOGY

The EANO Seminars are educational events designed to provide comprehensive updates on recent advances in the pathogenesis and management of central nervous system (CNS) tumours, with particular emphasis on their application in clinical practice. The EANO Seminars are intended for physicians from all disciplines involved in the care of patients with brain tumours, as well as nurses, researchers, technicians, and allied health professionals with an interest in neuro-oncology. A special focus is placed on young and early-career EANO members. We are pleased to announce that the next EANO Seminars will take place in Bucharest, Romania, from 13–14 March 2026, and will welcome more than 60 participants from across Europe.

REPORT ON EANO'S SOCIAL MEDIA ACTIVITIES 2025


In 2025, the EANO achieved strong growth across all social media platforms.

LinkedIn remained the leading channel for our international community, rising to more than 2,400 followers. Instagram grew dynamically and tripled its reach to more than 615 followers, driven by visual content, event highlights and Youngsters activities. The newly launched Bluesky channel was successfully established and quickly expanded to 440 followers, particularly within the academic community. Facebook showed moderate but steady growth and continues to serve as a complementary platform for broader audiences.

Overall, the EANO gained more than 2,100 new followers in 2025 – fuelled by professional science communication, strong conference visibility and an expanding international community.

Outlook for 2026: The focus will be on further strengthening LinkedIn as the primary communication channel, establishing regular content series such as Paper Highlights, EANO 2026, News and EANO Essentials, and expanding Bluesky as an increasingly important scientific network. We look forward to connecting with you on social media!

FOLLOW US!



EANO AWARDS WINNERS



**EANO Research Award
of the Year 2025**

Felix Sahm

© Private archive



**EANO Diversity and Inclusion
Award 2025**

Florian Boele

© Private archive



**EANO Nurse & Allied Health
Professional Research Award 2025**

Maija Reblin


© Private archive



**EANO Mentor Award
2025**

Matthias Preusser

© Private archive



**EANO Youngsters Award
2025**

Jan Resik

© Private archive



**EANO Research Grant Award
2025**

Aurélie Poli

© Luxembourg Institute of Health

EANO YOUNG INVESTIGATOR TRAVEL SCHOLARSHIP 2025:

- Philipp Karschnia
- Nikolay Yordanov
- Zan Florjanic Baronik
- Anna Mathioudaki
- Maximilian Mair
- Francesco Bruno
- Emma Rammeloo
- Valentino Ribecco

EANO INVESTIGATOR TRAVEL SCHOLARSHIP FOR OUTSTANDING SCIENCE FOR EANO ALLIED HEALTH PROFESSIONALS AND NURSES MEMBERS 2025:

- Shaista Meer
- Sarah Kendal
- Lotta Weyhenmeyer
- Åsa Munkhammar
- Helle Sørensen von Essen

EANO-SNO SCHOLARSHIP 2025:

- Jasper Gerritsen
- Maciej Pelak

EANO INTERNATIONAL OUTREACH TRAVEL SCHOLARSHIP 2025:

- You Zha

EANO NURSE & ALLIED HEALTH PROFESSIONALS (NAC) TRAVEL SCHOLARSHIP 2025:

- Ingrid Berggren
- Loredana Dinapoli
- Andrea Riol Elustondo

EANO DISPARITY TRAVEL SCHOLARSHIPS FOR EANO MEMBERS FROM UNDERREPRESENTED COUNTRIES 2025:

- Muhammad Alifian Remifta Putra
- Monica D'Alma Costa Santos
- Rafael Maffei

EANO 2025 RECAP AND FUTURE MEETINGS


The annual **EANO Meeting** took place in the beautiful city of **Prague** from **October 16–19, 2025**, and marked one of the most successful gatherings in the history of our association. With a record number of abstracts submitted and an exceptional level of participation, the meeting underscored EANO's role as a central and growing hub for the global neuro-oncology community. Attendees were particularly attracted by the multidisciplinary of the sessions and the breadth as well as depth of the scientific content spanning from groundbreaking basic science to practice changing clinical applications with ample opportunity for young clinicians and researchers to showcase their work and enter into meaningful discussions and networking.



The program opened with an Educational Day tailored to the needs of basic scientists, clinicians, nurses, and allied health professionals. It was followed by three days of stimulating scientific sessions that highlighted recent advances in diagnostics, therapeutic strategies, clinical trials, translational research, and emerging technologies. The diversity of topics, combined with the high quality of presentations and discussions, demonstrated the strong scientific momentum across the field. For the first time there was participation of patient representatives and caregivers owing to the impactful activities of the newly formed Brain Tumor Advocacy Committee.

This year's meeting also reflected the continued dedication of all committees, task forces, and initiatives whose collective efforts ensure EANO's educational and scientific standards remain at the highest level. We extend our gratitude to everyone involved in the planning and execution of the meeting, as well as to the many members who contributed abstracts, posters, oral presentations, and expert insights.

As we look ahead, preparations are well underway for our next annual meeting in Rome, which promises another inspiring event. We are excited to welcome the community to this historic city, where we will continue our mission to support scientific excellence, foster collaboration, and strengthen interdisciplinary exchange.

EANO extends its warm thanks to all participants and contributors who made the Prague meeting a success. We look forward to seeing you next year in Rome.







EANO MEETING 2026

Giuseppe Minniti and Michael Platten

Dear EANO members, colleagues and friends,

The **21st Meeting of the European Association of Neuro-Oncology (EANO 2026)** will be held in **Rome (Italy)**. Rome is the capital of Italy and one of the most important and fascinating cities in the world. Founded, according to legend, in 753 BC, it was the center of the Roman Empire, becoming the heart of one of the greatest empires in history. For this reason, it is called the Eternal City, a symbol of continuity and greatness. Strolling through Rome, you can admire unique monuments such as the Colosseum, the Roman Forum, the Pantheon, and famous squares such as Piazza Navona and the Spanish Steps, which have served as film sets for some of Hollywood's greatest films. Rome is also home to the Vatican, the heart of Christianity, with St. Peter's Basilica and the Sistine Chapel. Today, it is a modern capital that blends art, history, and daily life, attracting millions of visitors each year. The annual EANO meeting will kick off with a multiprofessional interdisciplinary Educational Day with separate tracks on Thursday, September 24 and the main scientific program will commence on Friday, September 25. The congress fosters exchange and collaboration between all stakeholders at all career stages in the field of neuro-oncology with students and professional experts in clinical and basic neuro-oncology, neurosurgery, neuropathology, neuroradiology and radiation oncology as well as nursing and other allied health professionals. It aims to bring together scientific and clinical expertise to bridge gaps in our understanding and management of nervous system tumors.

EANO is Europe's multidisciplinary neuro-oncology organisation representing all medical and scientific disciplines involved in the prevention, diagnosis, and treatment of tumors of the central and peripheral nervous system including neurology, neurosurgery, radiation oncology, medical oncology, pediatric neuro-oncology, neuropathology complemented by a vibrant basic science community. The successful 2025 EANO meeting in Prague attracted more than 1500 participants from all continents and was very highly rated!

Throughout the congress, speakers from around the world will share the latest clinical trial results, as well as key innovations in neuro-oncology, from basic science breakthroughs and advances in precision diagnostics to innovative local and systemic treatment modalities.

Save the date for Europe's largest neuro-oncology congress that attracts participants from all over the world!

Giuseppe Minniti
President EANO Meeting 2026

& Michael Platten
EANO President

EANO 2026 ROME

Auditorium Parco della Musica Ennio Morricone • Rome, Italy



eano
EUROPEAN ASSOCIATION
OF NEURO-ONCOLOGY
WWW.EANO.EU

**21ST MEETING
& EDUCATIONAL DAY
SEPTEMBER 24-27, 2026**



EANO Office
European Association of Neuro-Oncology

Alser Straße 4 | 1090 Vienna | Austria

[t] 0043 (0)1 405 13 83 - **31** or **43**

[e] office@eano.eu

[w] www.eano.eu

© all rights reserved by the European Association of Neuro-Oncology